Celltrion Inc. Company Profile

18:04 EST 19th January 2019 | BioPortfolio

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Celltrion also received EMA approval for Truxima® (CT-P10, a mAb biosimilar to MabThera®iv (rituximab)) in February 2017. For more information, visit

News Articles [99 Associated News Articles listed on BioPortfolio]

Federal judge: Celltrion's Inflectra does not infringe on Remicade patent

Celltrion won against Johnson & Johnson unit Janssen Biotech's patent-infringement lawsuit regarding Celltrion's biosimilar I -More- 

FDA panel endorses Celltrion’s biosimilar to Rituxan

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has recommended approval of Celltrion’s Rituxan biosimilar CT-P10. CT-P10...Read More... The post FDA panel endor...

Celltrion hit with Form 483 over troublesome Incheon plant

Celltrion has told shareholders its manufacturing site received a Form 483 from the US FDA.

Celltrion calls for wider use of biologics in RA

Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to...

Celltrion hopes to outdo inflammatory disease rivals with SC infliximab

South Korea’s Celltrion has made its name with biosimilars – near copies of biologic drugs – but is hoping to go one better with a subcutaneously administered version of infliximab that will be ...

Teva, Celltrion get FDA nod for Roche’s breast cancer drug biosimilar

Herzuma, which is a HER2/neu receptor antagonist biosimilar to Herceptin, has been approved to treat HER2-overexpressing breast cancer for certain indications. Celltrion CEO Woosung Kee said: “Biosi...

Celltrion's Rituxan biosimilar wins FDA nod

The FDA granted approval to Celltrion's Truxima, a biosimilar version of Roche's Rituxan that is indicated for the treatment  -More- 

Celltrion gets FDA clearance for biosimilar Truxima

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis

A new subcutaneous infliximab formulation is being developed by Celltrion, Inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less th...

Companies [5 Associated Companies listed on BioPortfolio]

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltr...

Celltrion, Inc.

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mA...


Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost ...

Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.

Celltrion Healthcare

Satellite symposium 3a: Remsima™, the 1st biosimilar monoclonal antibody, Friday 20 February 07:15-08:15

More Information about "Celltrion Inc." on BioPortfolio

We have published hundreds of Celltrion Inc. news stories on BioPortfolio along with dozens of Celltrion Inc. Clinical Trials and PubMed Articles about Celltrion Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celltrion Inc. Companies in our database. You can also find out about relevant Celltrion Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Corporate Database Quicklinks

Searches Linking to this Company Record